Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Cell Dev. Biol., 06 February 2026

Sec. Stem Cell Research

Volume 14 - 2026 | https://doi.org/10.3389/fcell.2026.1695559

Bioinspired artificial nanovesicles engineered from 3D spheroid-cultured UC-MSCs enhance angiogenic activity in vitro: functional proof-of-concept for ischemic applications

  • 1Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
  • 2Cardiovascular Research Institute, Kyungpook National University, Daegu, Republic of Korea
  • 3BK21 FOUR KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, Department of Biomedical Sciences, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
  • 4Department of Nuclear Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea

Artificial nanovesicles (aNVs) derived from cells may mimic naturally secreted extracellular vesicles (EVs) and are becoming popular in biomedical research. We isolated aNVs from two-dimensional (2D)- and three-dimensional (3D)-cultured umbilical cord-derived mesenchymal stem cells (UC-MSCs) (aNVs2D and aNVs3D, respectively) and characterized them using Western blotting and electron microscopy. The aNVs3D showed higher expression of IL-6 and SDF-1α than aNVs2D. In vitro treatment with aNVs2D and aNVs3D resulted in their internalization into endothelial cells and the subsequent alteration of endothelial cell proliferation, migration, and tube formation. Both aNVs were positive for EVs and cell markers and were round in shape. Furthermore, aNVs3D treatment enhanced endothelial cell proliferation, migration, and tube formation more effectively than aNVs2D treatment. Our study demonstrates that aNVs3D are potent inducers of angiogenesis, indicating their potential in cell-free ischemia treatment.

GRAPHICAL ABSTRACT
Scientific diagram showing the process of creating artificial nanovesicles (aNVs) from two-dimensional and three-dimensional umbilical cord mesenchymal stem cells (UC-MSCs), extrusion steps, and their effects on endothelial cell proliferation, migration, and tube formation, with specific mention of increased IL-6 and SDF-1α for aNVs3D.

GRAPHICAL ABSTRACT |

1 Introduction

Ischemic diseases, such as peripheral artery disease (PAD) and critical limb ischemia (CLI), pose significant clinical challenges by impairing blood flow, resulting in tissue necrosis and potential limb amputation (Ravi Mythili et al., 2025; Zemaitis et al., 2025). PAD is a widespread vascular condition that affects more than 200 million adults globally. The incidence of PAD has increased dramatically, reaching up to 20% in individuals aged ≥70 years (Zemaitis et al., 2025). Current therapeutic strategies, including drug administration (Arabzadeh et al., 2023), cell-based therapies (Desai et al., 2024; Huang et al., 2024), and surgical revascularization (Yuksel et al., 2018), have exhibited limited success in functional recovery. Hence, the development of a new and efficient therapeutic strategy is urgently required for effectively restoring vascularization in patients with ischemia.

Extracellular vesicles (EVs) are nanosized vesicles that are naturally secreted by almost all cells. They can carry and deliver bioactive biological materials, such as lipids, proteins, and nucleic acids (miRNA, mRNA, and DNA), to recipient cells and act as natural modulators in cell-to-cell communication (Rajendran et al., 2025a; Gangadaran et al., 2024); they can thus be used for treating diseases (Che Shaffi et al., 2024). EVs, particularly those derived from mesenchymal stem cells (MSCs), have emerged as promising candidates for regenerative therapies because of their ability to modulate angiogenesis, inflammation, and tissue regeneration (Samadi et al., 2025; Kumar et al., 2024). However, the clinical application of naturally secreted MSC-derived EVs is often hindered by their limited yield (Rajendran et al., 2025b). To overcome this limitation, engineered artificial nanovesicles (aNVs) have been developed as a bioinspired alternative that can mimic the functional properties of natural EVs with scalable production (Li et al., 2025; Lou et al., 2025; Li et al., 2024).

Recent studies suggest that the microenvironment in which MSCs are cultured significantly influences their secretory profile and therapeutic potential (Han et al., 2022; Xue et al., 2024). Although conventional two-dimensional (2D) culture systems have provided valuable insights into the biology and regenerative potential of MSCs, they fail to fully replicate the native three-dimensional (3D) microenvironment (Antoni et al., 2015; Yen et al., 2023). Notably, 3D spheroid culture conditions have been shown to enhance the paracrine effects of MSCs, enriching their secretome with proangiogenic factors (Han et al., 2022; Rajendran et al., 2024; Gangadaran et al., 2023). Therefore, we hypothesized that the 3D culture environment of cells enhances the production of angiogenic molecules, which could be transferred to engineered aNVs from 3D-cultured cells.

In this study, we assessed the potential of aNVs engineered from 3D spheroid-cultured umbilical cord-derived MSCs (UC-MSCs3D) (hereafter, aNVs3D) as novel proangiogenic therapeutic agents for promoting angiogenesis. We compared the therapeutic effects of engineered aNVs derived from 2D UC-MSC cultures (UC-MSCs2D) (hereafter, aNVs2D) and aNVs3D on endothelial cells in vitro. Our findings provide valuable insights into the potential of aNVs3D as a promising cell-free therapeutic strategy for ischemic diseases, paving the way for translational applications in regenerative medicine.

2 Materials and methods

2.1 Cells

Human UC-MSCs were purchased from the American Type Culture Collection (ATCC, Manassas, VA, United States) and cultured in the Mesenchymal Stem Cell Growth Kit-Low Serum for Adipose and Umbilical Cord-Derived MSCs (ATCC). Mouse endothelial cells (SVEC4-10EHR1) were purchased from ATCC and cultured in DMEM (Gibco, Carlsbad, CA, United States) supplemented with 10% FBS. All cells were maintained with 1% penicillin/streptomycin (Gibco) at 37 °C.

2.2 Monolayer 2D and 3D spheroid cultures

To generate UC-MSCs2D, UC-MSCs were cultured in flat bottom plates. To generate UC-MSCs3D, UC-MSCs (1X104) were cultured in U-shaped 96-well plates as described previously (Rajendran et al., 2024). The morphology of UC-MSCs3D was confirmed on day 5 by using a Nikon Eclipse Ti fluorescence microscope (Nikon Corp., Tokyo, Japan).

2.3 Engineering of aNVs

UC-MSCs2D and UC-MSCs3D were dissociated into single cells by gentle pipetting. Subsequently, aNVs were generated using a previously described method (Gopal et al., 2024). In brief, the cells were serially extruded five times through 10-μm, 5-μm, and 1-μm polycarbonate membrane filters (Nuclepore, Whatman, Inc., Clifton, NJ, United States) using a mini-extruder (Avanti Polar Lipids, Birmingham, AL, United States). The extruded sample was centrifuged at 4,000 × g for 10 min and subsequently filtered through a 0.45-μm filter. The samples were then ultracentrifuged at 100,000 × g for 1 h at 4 °C. The resuspended sample was further purified by performing differential gradient ultracentrifugation using OptiPrep density gradient medium (Iodixanol, Sigma-Aldrich, St. Louis, MO, United States) at 100,000 × g for 3 h at 4 °C. Following this, aNVs2D and aNVs3D were collected from the interface of the 60% and 20% iodixanol layers. The collected aNVs were then stored at −80 °C. The protein concentration in the aNVs was measured using the BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, United States).

2.4 Western blotting

Western blotting was performed as described previously (Gopal et al., 2024). In brief, total proteins from the aNVs2D and aNVs3D were extracted in radioimmunoprecipitation assay (RIPA) buffer (Thermo Fisher Scientific, Waltham, MA, United States) and equally loaded of 10 µg protein per lane and separated using 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis. The samples were then transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Burlington, MA, United States). The membranes were blocked with 5% skim milk and probed with primary antibodies against ALIX, CD63, flotillin-1, and calnexin and then with a horseradish peroxidase-conjugated secondary antibody (Cell Signaling Technology, Danvers, MA, United States). After incubating the membrane with an enhanced chemiluminescence (ECL) solution (GE Healthcare Systems, Buckinghamshire, United Kingdom), the signals were observed using a chemiluminescence analyzer system (Vilber Lourmat, Marne-la-Vallée Cedex, France).

2.5 Transmission electron microscopy (TEM)

The aNVs2D and aNVs3D were visualized using TEM as described previously (Gangadaran et al., 2018). In brief, the aNVs2D and aNVs3D were resuspended in 2% paraformaldehyde for fixation. Subsequently, they were adsorbed onto Formvar–carbon-coated electron microscopy grids (Electron Microscopy Sciences, United States), air-dried, and fixed with 1% glutaraldehyde for 5 min at room temperature. The aNVs2D and aNVs3D on the grids were then negatively stained with 2% uranyl acetate, washed seven times with PBS, air-dried, and examined using TEM (HT 7700; Hitachi, Japan) at 100 kV.

2.6 Human cytokine array

Proteins extracted from aNVs2D and aNVs3D (50 µg per blot) were subjected to cytokine profiling using a Human Cytokine Array (RayBiotech, Peachtree Corners, GA, United States) according to the manufacturer’s instructions. Signal intensities were quantified using GelQuant.NET software (version 1.8.2; Biochem Lab Solutions, San Francisco, CA, United States) and represented in fold change after normalizing with positive control.

2.7 Internalization assay

The aNVs2D and aNVs3D were incubated with Vybrant™ DiD Cell-Labeling Solution (Thermo Fisher Scientific, Waltham, MA, United States) for 20 min. They were then reconstituted with PBS. The samples were processed in OptiPrep density gradient medium (Iodixanol, Sigma-Aldrich, St. Louis, MO, United States) at 100,000 × g for 3 h at 4 °C. The Dil-labeled aNVs2D and aNVs3D [aNVs2D (DiD) and aNVs3D (DiD), respectively] were collected from the interface as mentioned above. Endothelial cells (5 × 103 cells/well) were cultured on eight-well slides and incubated overnight at 37 °C in 5% CO2. On the next day, 10 μg/mL of the aNVs2D, aNVs3D, aNVs2D (DiD), and aNVs3D (DiD) were incubated with endothelial cells for 2 h at 37 °C in 5% CO2. The slides were subsequently fixed with methanol and mounted using Vectashield antifade mounting medium with DAPI (Vector Laboratories, Burlingame, CA, United States). The internalization of aNVs2D (DiD) and aNVs3D (DiD) was observed under an AXIO microscope (Zeiss, Oberkochen, Baden-Württemberg, Germany).

2.8 Cell proliferation assay

Endothelial cells (2 × 104 cells/well) were seeded in a 96-well plate and incubated overnight at 37 °C in 5% CO2. The cells were then treated with varying concentrations of aNVs2D and aNVs3D (0, 2.5, 5, 7.5, and 10 μg/mL) and incubated at 37 °C in 5% CO2. After 12 and 24 h, 10 μL of the Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan) reagent was added to each well and incubated for another 2 h at 37 °C in 5% CO2. Absorbance was then measured at 450 nm using a microplate reader, according to the manufacturer’s protocol.

2.9 Transwell migration assay

Transwell migration assays were performed in 24-well cell culture inserts containing an 8.0-µm-pore-size transparent PET membrane (BD Biosciences, Franklin Lakes, NJ, United States). Endothelial cells (5 × 104 cells/insert) were plated in each upper insert with 0.5 mL of serum-free medium and treated with PBS (control), aNVs2D, or aNVs3D (10 μg/mL each). Complete medium supplemented with 10% FBS was placed in the lower chamber and incubated at 37 °C in 5% CO2. After 12 and 24 h, the cells on the lower surface were fixed, stained with crystal violet, and imaged using a Nikon Eclipse Ti fluorescence microscope (Nikon Corp., Tokyo, Japan). The number of cells was counted in the captured field of images.

2.10 Tube formation assay

Matrigel Growth Factor Reduced (GFR) Basement Membrane Matrix (100% concentration) (Matrigel; Corning, Merck KGaA, Darmstadt, Germany) was coated onto 24-well plates and incubated at 37 °C in 5% CO2 for 1 h. Subsequently, 5 × 105 endothelial cells were seeded onto the Matrigel. The endothelial cells were then treated with PBS (control), aNVs2D, or aNVs3D (10 μg/mL each) and incubated at 37 °C in 5% CO2 at reduced FBS (2.5%) media. Tube formation ability was assessed after 3 h and 6 h under an AXIO microscope (Zeiss, Baden-Württemberg, Germany). The vessel percentage area, total vessel area, junction density, and total vessel length within the tubular structures were measured using AngioTool software (National Cancer Institute, Radiation Oncology Branch, Angiogenesis Core Facility, MD, United States).

2.11 Declaration of generative AI and AI-assisted technologies in the writing process

During the preparation of this work, the authors used Wordvice AI for proofreading and grammar checking. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.

2.12 Statistical analysis

All data are expressed as the means ± standard deviations (SDs). The differences between pairs of groups were statistically analyzed using Student’s t-test or Two-way ANOVA in Excel (Microsoft) or GraphPad Prism 10.6.1.892 (GraphPad Software Inc., San Diego, CA, United States). p < 0.05 was considered statistically significant.

3 Results

3.1 Establishment of UC-MSCs2D and UC-MSCs3D

Figure 1A illustrates the establishment of UC-MSCs2D and UC-MSCs3D. As shown in the representative images, In the 2D cultures, the UC-MSCs adhered to the surface of the flat bottom plate and exhibited a characteristic spindle-shaped morphology. In contrast, after 5 days of culture in U-shaped 96-well plates, UC-MSCs3D appeared as aggregated 3D spheres (Figure 1B). These results indicate the successful establishment of UC-MSCs3D.

Figure 1
Panel A contains a diagram showing umbilical cord-derived mesenchymal stem cells (UC-MSCs) cultured on a flat surface plate to produce two-dimensional cells or on a U-shaped ninety-six well plate to produce three-dimensional spheroids. Panel B displays microscopy images, with the top image showing elongated, flattened two-dimensional UC-MSCs and the bottom image showing a rounded, three-dimensional spheroid of UC-MSCs after five days.

Figure 1. Establishment of 2D and 3D Cultures of Umbilical Cord-Derived Mesenchymal Stem Cells. (A) Schematic representation of 2D and 3D UC-MSC cultures, created with BioRender.com. (B) Images of 2D cultures of MSCs (UC-MSCs2D) in flat bottom plates and 3D cultures of MSCs (UC-MSCs3D) in U-shaped 96-well plates, with UC-MSCs3D cultured up to day 5 (scale bar: 500 pixels).

3.2 Generation and characterization of aNVs2D and aNVs3D

UC-MSCs2D and UC-MSCs3D (dissociated by gentle pipetting) were extruded five times through membranes of various sizes (10, 5, and 1 µm), filtered, isolated, and purified to generate aNVs2D and aNVs3D, respectively (Figure 2A). EVs and cell markers in both aNVs2D and aNVs3D were assessed using Western blotting. The analysis revealed that both aNVs2D and aNVs3D expressed the key EV markers ALIX, CD63 and flotillin-1 and the cellular marker calnexin (Figure 2B). TEM further revealed that both aNVs2D and aNVs3D exhibited a distinct spherical morphology (Figure 2C). Eighty human cytokines in aNVs2D and aNVs3D were analyzed by a human cytokine array, several cytokines were differently expressed in aNVs2D and aNVs3D. Among the cytokines upregulated in aNVs3D, interleukin-6 (IL-6) and stromal cell–derived factor-1α (SDF-1α; CXCL12), are well-recognized regulators of angiogenesis (Figure 2D). These results indicate the successful generation and characterization of aNVs2D and aNVs3D and along with enrichment of angiogenic factors.

Figure 2
Panel A shows a schematic workflow for isolating extracellular vesicles from UC-MSCs cultured in 2D and 3D, involving serial filtration, ultracentrifugation, and gradient separation. Panel B presents western blot results validating ALIX, CD63, Flotillin-1, and Calnexin proteins in aNVs extracted from 2D and 3D cultures. Panel C includes transmission electron microscopy images displaying the morphology and size distribution of aNVs from both culture conditions, with enlarged insets highlighting individual vesicles. Panel D depicts cytokine array results comparing IL-6 and SDF-1α levels in aNVs from 2D and 3D, accompanied by a bar graph quantifying relative cytokine abundance.

Figure 2. Generation and Characterization of aNVs2D and aNVs3D. (A) Graphical illustration of the generation of aNVs2D and aNVs3D from UC-MSCs2D and UC-MSCs3D, respectively, created with BioRender.com. (B) Western blot analysis of aNVs2D and aNVs3D (10 µg protein per lane) using antibodies against ALIX, CD63, flotillin-1, and calnexin. (C) TEM imaging of aNVs2D and aNVs3D (scale bar: 200 nm). (D) An array blot incubated with aNVs2D and aNVs3D lysate (50 µg per blot), the fold change of highly expressed cytokines was presented in graph.

3.3 Internalization of aNVs2D and aNVs3D into endothelial cells

The internalization of aNVs is important for therapeutic purposes because it allows the cargo of aNVs to be delivered into recipient cells8,22. The active internalization of aNVs2D and aNVs3D was assessed using a fluorescence-based technique. In brief, aNVs2D and aNVs3D were labeled with the lipophilic dye DiD, and unlabeled aNVs2D, unlabeled aNVs3D, aNVs2D (DiD), and aNVs3D (DiD) were then incubated with endothelial cells. Fluorescence microscopy images demonstrated that both aNVs2D (DiD) and aNVs3D (DiD) were actively internalized into endothelial cells. This internalization was predominantly observed within the cytoplasm. No signals were observed in unlabeled aNVs2D and aNVs3D incubated with endothelial cells (Figure 3). These results indicate that both aNVs2D (DiD) and aNVs3D (DiD) targeted and were internalized into endothelial cells.

Figure 3
Fluorescence microscopy panel showing cells labeled with DiD (red) and DAPI (blue), followed by brightfield, overlay, and zoom images for aNVs2D and aNVs3D groups with and without DiD. Overlay images demonstrate colocalization of red and blue signals within cellular regions, further highlighted in the zoom panels.

Figure 3. Internalization of aNVs2D and aNVs3D into Endothelial Cells. Fluorescence microscopy images demonstrate the internalization of aNVs2D (DiD) and aNVs3D (DiD) into endothelial cells (scale bar: 20 µm).

3.4 aNVs3D accelerated the proliferation and migration of endothelial cells

Endothelial cells were treated with aNVs2D and aNVs3D (0, 2.5, 5, 7.5, and 10 μg/mL) for 12 h and 24 h, and their proliferation was assessed using the CCK-8 assay. Cell proliferation was enhanced on treatment with aNVs2D and aNVs3D. Treatment with aNVs3D increased endothelial cell proliferation significantly more effectively than treatment with aNVs2D at all tested concentrations and two time points (two-way ANOVA, p < 0.001 to p < 0.0001). (Figure 4A). The migration of endothelial cells is crucial for sprouting, which results in blood vessel formation. Therefore, endothelial cell migration was performed as illustrated in Figure 4B. The transwell migration assay demonstrated that both aNVs2D and aNVs3D (5 and 10 μg/mL) enhanced endothelial cell migration at 12 h and 24 h compared to the control across all tested concentrations and two time points (two-way ANOVA, p < 0.001 to p < 0.0001). Notably, aNVs3D induced a higher migration rate than aNVs3D (Figures 4C,D).

Figure 4
Figure containing four panels: A, a bar graph comparing proliferation percentages of endothelial cells treated with different concentrations of aNVs2D and aNVs3D at 12 and 24 hours, showing increased proliferation with higher concentrations and time; B, a schematic diagram illustrating a transwell migration assay setup with endothelial cells migrating through a membrane towards a chemoattractant; C, representative microscope images of migrated endothelial cells stained purple for control and treated groups at 12 and 24 hours, with more migration observed in treated groups, especially aNVs3D; D, a bar graph quantifying migrated cells for control and treated conditions, indicating significant increases for higher concentrations, timepoints, and the aNVs3D group.

Figure 4. aNVs3D Promoted the Proliferation and Migration of Endothelial Cells. (A) Endothelial cells were treated with aNVs2D and aNVs3D (0, 2.5, 5, and 10 μg/mL) for 12 h and 24 h, and cell proliferation (n = 4) was assessed using the CCK-8 assay. (B) Illustration of the experiment to assess endothelial cell migration following treatment with aNVs, created with BioRender.com. (C) Representative image of transwell migration of endothelial cells treated with aNVs2D and aNVs3D (5 and 10 μg/mL) at 12 h and 24 h (scale bar: 100 µm). (D) Quantitative analysis of the transwell migration assay presented in (C) (n = 3). Statistical significance is denoted as follows: *p < 0.05; **p < 0.01, ***p < 0.001 and ****p < 0.0001, as determined by Two-way ANOVA.

3.5 aNVs3D promoted vessel-like tube formation in vitro

The effect of aNVs3D on in vitro capillary-like network formation was assessed using a tube formation assay in Matrigel. Endothelial cells were treated with aNVs2D and aNVs3D for 3 and 6 h. Subsequently, microscopic images were taken for visualizing vessel-like tube formation (Figures 5A,C). The images were assessed using AngioTool. Quantitative results at 3 h revealed that treatment with aNVs3D promoted the vessel percentage area, total vessel area, junction density, and total vessel length compared to treatment with aNVs2D and the control (p < 0.05 or p < 0.01) (Figure 5B). At 6 h, Quantitative assessment showed that both aNVs2D and aNVs3D significantly enhanced vessel area, vessel percentage area, junction density, and total vessel length relative to the control (p < 0.05 or p < 0.01). Importantly, aNVs3D induced significantly greater vessel area and vessel percentage area compared with aNVs2D (*p < 0.05), suggesting superior angiogenic efficacy. While junction density and total vessel length were also higher in the aNVs3D group than in the aNVs2D group, these differences showed a strong increasing trend but did not reach statistical significance (p = 0.088 and p = 0.071, respectively) (Figure 5D). These findings suggest that treatment with aNVs3D is more effective in promoting capillary-like network formation than treatment with aNVs2D.

Figure 5
Panel A includes six microscope images showing vessel formation over time with three conditions: Control, aNVs2D, and aNVs3D, at three hours and six hours. Panels B and D present eight bar graphs depicting quantitative comparisons of vessel area, vessel percentage area, junctions density, and total vessel length among the same three groups, with statistical significance indicated by asterisks and a notation of

Figure 5. aNVs3D Promoted Vessel-Like Tube Formation In Vitro. (A,B) Representative microscopic images showing vessel-like tube formation by endothelial cells treated with aNVs2D and aNVs3D in Matrigel (scale bar: 100 µm) at 3 h and 6 h (C,D) Quantification of % of vessel percentage area total vessel area, junctions density, and total vessels length analyzed using AngioTool for (A) (n = 3). Statistical significance determined by Student’s t-test is denoted as follows. ns: no significance, *p: <0.05, and **p: <0.01.

4 Discussion

Stem cells have garnered significant attention as a promising new treatment for PAD and CLI (Samura et al., 2017). Most of the therapeutic effects of MSCs are attributed to secretory factors, including EVs. Most studies have utilized natural MSC-derived EVs for the treatment of ischemic diseases (Gregorius et al., 2021; Gangadaran et al., 2021; Gangadaran et al., 2017). However, achieving therapeutic outcomes from natural EVs is a lengthy process that requires the collection of large volumes of conditioned media and extensive cell expansion (Fan et al., 2020; Hao et al., 2021). In this study, aNVs3D were created to address the limitations of natural EVs derived from 2D cells that are currently used in research on angiogenesis and ischemic diseases. The rationale for employing 3D spheroid culture is its capacity to more accurately replicate the native stem cell microenvironment, thereby enhancing cellular interactions and the secretion of therapeutic factors (Yen et al., 2023; Gao et al., 2024; Lu et al., 2024).

The 3D cell culture model can be developed using either scaffold-free methods, in which cells aggregate without an extracellular matrix (ECM), or scaffold-based approaches, in which cell growth occurs within an ECM environment (Lee et al., 2023). In this study, we used scaffold-free methods and generated UC-MSCs3D in a U-shaped 96-well plate. Unlike other methods, this method facilitates easy collection of spheroids with uniform size (Chaicharoenaudomrung et al., 2019; Kim et al., 2024). In our study, the 3D spheroids showed consistent uniform size on day 5, indicating that each spheroid was cultured under the same culture condition and was likely to have the same biological characteristics, as reported previously (Lee et al., 2023). Hence, the generation of aNVs from uniform 3D spheroid-derived cells yields a more homogeneous therapeutic outcome than that from heterogeneous 3D spheroid cells.

aNVs2D and aNVs3D were engineered from UC-MSCs2D and UC-MSCs3D, respectively, by serial extrusion with 10, 5, and 1 µM polycarbonate membranes, which NVs form via the self-assembly of lipid bilayer pieces from fragmented cells into vesicles, and were further purified through filtration and gradient ultracentrifugation. Our Western blot analysis revealed that both aNVs2D and aNVs3D were positive for EV markers, such as ALIX, CD63 and flotillin-1 (Hessvik and Llorente, 2017), indicating that aNVs are made of cell membranes, such as EVs. In addition, both aNVs2D and aNVs3D were positive for calnexin, an endoplasmic reticulum marker that is considered a negative marker for natural EVs. While natural EVs may only carry some cellular content, aNVs can theoretically encapsulate the entire cellular content (Sun et al., 2022). Both aNVs2D and aNVs3D were confirmed to be round in shape, consistent with the findings of previous studies on the generation of aNVs (Jang et al., 2013; Li et al., 2022). aNVs3D exhibited enhanced angiogenic factors (Cohen et al., 1996; Ababneh et al., 2025) such as IL-6 and SDF-1α (CXCL12) compared with aNVs2D, this may enhance angiogenic effect of aNVs3D as both are key pro-angiogenic cytokines. Consistent with our findings, previous studies have demonstrated that 3D culture enhanced the pro-angiogenic factors in cells, secretory factors including EVs (Ababneh et al., 2025; Rovere et al., 2023; Gangadaran et al., 2023).

The internalization of aNVs into cells is crucial for their therapeutic potential, enabling the delivery of functional biological materials and the activation of intracellular signaling pathways (Li et al., 2025). In our study, aNVs2D and aNVs3D actively interacted with endothelial cells and were internalized into them. During angiogenesis, i.e., the process of forming new blood vessels, endothelial cell proliferation (growth and division) is crucial for the expansion of the existing vascular network (Lorenc et al., 2024). We assessed whether internalization causes any changes in endothelial cell proliferation. Treatments with aNVs2D and aNVs3D augmented the proliferation of endothelial cells, with aNVs3D inducing higher endothelial cell proliferation than aNVs2D. The migration of endothelial cells is the next step in the formation of new blood vessels (Michaelis, 2014). Treatment with aNVs3D enhanced the migration of endothelial cells more effectively than treatment with aNVs2D. Our results revealed that aNVs3D exhibited enhanced angiogenic effects, proving that 3D culture enhanced the angiogenic factors in cells that were eventually transferred to aNVs3D. Consistent with our findings, previous study has demonstrated that 3D MSC-derived EVs exhibit superior pro-proliferative enhanced migration, and improved tube formation effects on endothelial cell compared with their 2D-derived EVs (Gao et al., 2021) and another study demonstrated that a 3D culture system significantly enhanced angiogenic therapeutic efficacy, showing improved pro-angiogenic activity in endothelial cells in vitro as well as superior functional recovery in an in vivo heart repair model (Sun et al., 2023). Hence, we hypothesized that aNVs3D can stimulate angiogenesis by inducing tube formation in endothelial cells. Compared to aNVs2D, aNVs3D significantly improved tube formation in endothelial cells under Matrigel conditions. Overall, our results suggest that UC-MSCs3D exhibit enhanced expression of proangiogenic factors, which are subsequently transferred to aNVs3D during their generation. However, our study has some limitations. Although in vitro data strongly support the angiogenic efficacy of aNVs3D, their in vivo performance in promoting neovascularization in ischemic tissues still needs to be assessed. Furthermore, comprehensive molecular profiling of the vesicle cargo (e.g., proteomics and transcriptomics) could offer deeper insights into the mechanistic basis of the observed effects.

In conclusion, our findings highlight that aNVs3D exhibit superior proangiogenic effects, representing a potent, scalable, and cell-free therapeutic strategy for ischemic diseases.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

Author contributions

PG: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing. RR: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing. JO: Data curation, Project administration, Software, Writing – review and editing. JS: Data curation, Formal analysis, Investigation, Methodology, Writing – review and editing. CH: Investigation, Methodology, Project administration, Software, Visualization, Writing – review and editing. B-CA: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing.

Funding

The author(s) declared that financial support was received for this work and/or its publication. This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2021R1I1A1A01040732).

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was used in the creation of this manuscript. During the preparation of this work, the authors used Wordvice AI for proofreading and grammar checking. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Ababneh, N. A., Alwohoush, E., AlDiqs, R., Ismail, M. A., Al-Kurdi, B., Barham, R., et al. (2025). Impact of differentiation protocols on the functionality of mesenchymal stem cells derived from induced pluripotent stem cells. World J. Stem Cells 17 (12), 110564. doi:10.4252/wjsc.v17.i12.110564

PubMed Abstract | CrossRef Full Text | Google Scholar

Antoni, D., Burckel, H., Josset, E., and Noel, G. (2015). Three-dimensional cell culture: a breakthrough in vivo. Int. J. Mol. Sci. 16 (3), 5517–5527. doi:10.3390/ijms16035517

PubMed Abstract | CrossRef Full Text | Google Scholar

Arabzadeh, A., Faghfuri, E., Razi Soofiyani, S., Dalir Abdolahinia, E., Siapush, S., Nejati-Koshki, K., et al. (2023). Current and novel emerging medical therapies for peripheral artery disease: a literature review. Adv. Pharm. Bull. 13 (2), 259–268. doi:10.34172/apb.2023.025

PubMed Abstract | CrossRef Full Text | Google Scholar

Chaicharoenaudomrung, N., Kunhorm, P., and Noisa, P. (2019). Three-dimensional cell culture systems as an in vitro platform for cancer and stem cell modeling. World J. Stem Cells 11 (12), 1065–1083. doi:10.4252/wjsc.v11.i12.1065

PubMed Abstract | CrossRef Full Text | Google Scholar

Che Shaffi, S., Hairuddin, O. N., Mansor, S. F., Syafiq, T. M. F., and Yahaya, B. H. (2024). Unlocking the potential of extracellular vesicles as the next generation therapy: challenges and opportunities. Tissue Eng. Regen. Med. 21 (4), 513–527. doi:10.1007/s13770-024-00634-4

PubMed Abstract | CrossRef Full Text | Google Scholar

Cohen, T., Nahari, D., Cerem, L. W., Neufeld, G., and Levi, B.-Z. (1996). Interleukin 6 induces the expression of vascular endothelial growth factor (∗). J. Biol. Chem. 271 (2), 736–741. doi:10.1074/jbc.271.2.736

PubMed Abstract | CrossRef Full Text | Google Scholar

Desai, S., Sharma, D., Srinivas, R., Balaji, V., Thakore, V., Bedi, V. S., et al. (2024). Mesenchymal stromal cell therapy (REGENACIP®), a promising treatment option in chronic limb threatening ischemia – a narrative review. Stem Cell Res. Ther. 15 (1), 352. doi:10.1186/s13287-024-03957-0

PubMed Abstract | CrossRef Full Text | Google Scholar

Fan, J., Lee, C.-S., Kim, S., Chen, C., Aghaloo, T., and Lee, M. (2020). Generation of small RNA-modulated exosome mimetics for bone regeneration. ACS Nano 14 (9), 11973–11984. doi:10.1021/acsnano.0c05122

PubMed Abstract | CrossRef Full Text | Google Scholar

Gangadaran, P., Rajendran, R. L., Lee, H. W., Kalimuthu, S., Hong, C. M., Jeong, S. Y., et al. (2017). Extracellular vesicles from mesenchymal stem cells activates VEGF receptors and accelerates recovery of hindlimb ischemia. J. Control. Release Off. J. Control. Release Soc. 264, 112–126. doi:10.1016/j.jconrel.2017.08.022

PubMed Abstract | CrossRef Full Text | Google Scholar

Gangadaran, P., Hong, C. M., Oh, J. M., Rajendran, R. L., Kalimuthu, S., Son, S. H., et al. (2018). Vivo non-invasive imaging of radio-labeled exosome-mimetics derived from red blood cells in mice. Front. Pharmacol. 9, 817. doi:10.3389/fphar.2018.00817

PubMed Abstract | CrossRef Full Text | Google Scholar

Gangadaran, P., Rajendran, R. L., Oh, J. M., Oh, E. J., Hong, C. M., Chung, H. Y., et al. (2021). Identification of angiogenic cargo in extracellular vesicles secreted from human adipose tissue-derived stem cells and induction of angiogenesis in vitro and in vivo. Pharmaceutics 13 (4), 495. doi:10.3390/pharmaceutics13040495

PubMed Abstract | CrossRef Full Text | Google Scholar

Gangadaran, P., Oh, E. J., Rajendran, R. L., Oh, J. M., Kim, H. M., Kwak, S., et al. (2023). Three-dimensional culture conditioned bone marrow MSC secretome accelerates wound healing in a burn injury mouse model. Biochem. Biophys. Res. Commun. 673, 87–95. doi:10.1016/j.bbrc.2023.05.088

PubMed Abstract | CrossRef Full Text | Google Scholar

Gangadaran, P., Khan, F., Rajendran, R. L., Onkar, A., Goenka, A., and Ahn, B.-C. (2024). Unveiling invisible extracellular vesicles: cutting-edge technologies for their in vivo visualization. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 16 (5), e2009. doi:10.1002/wnan.2009

PubMed Abstract | CrossRef Full Text | Google Scholar

Gao, W., Liang, T., He, R., Ren, J., Yao, H., Wang, K., et al. (2021). Exosomes from 3D culture of marrow stem cells enhances endothelial cell proliferation, migration, and angiogenesis via activation of the HMGB1/AKT pathway. Stem Cell Res. 50, 102122. doi:10.1016/j.scr.2020.102122

PubMed Abstract | CrossRef Full Text | Google Scholar

Gao, Q., Cekuc, M. S., Ergul, Y. S., Pius, A. K., Shinohara, I., Murayama, M., et al. (2024). 3D culture of MSCs for clinical application. Bioeng. Basel Switz. 11 (12), 1199. doi:10.3390/bioengineering11121199

PubMed Abstract | CrossRef Full Text | Google Scholar

Gopal, A., Gangadaran, P., Rajendran, R. L., Oh, J. M., Lee, H. W., Hong, C. M., et al. (2024). Extracellular vesicle mimetics engineered from mesenchymal stem cells and curcumin promote fibrosis regression in a mouse model of thioacetamide-induced liver fibrosis. Regen. Ther. 26, 911–921. doi:10.1016/j.reth.2024.10.005

PubMed Abstract | CrossRef Full Text | Google Scholar

Gregorius, J., Wang, C., Stambouli, O., Hussner, T., Qi, Y., Tertel, T., et al. (2021). Small extracellular vesicles obtained from hypoxic mesenchymal stromal cells have unique characteristics that promote cerebral angiogenesis, brain remodeling and neurological recovery after focal cerebral ischemia in mice. Basic Res. Cardiol. 116 (1), 40. doi:10.1007/s00395-021-00881-9

PubMed Abstract | CrossRef Full Text | Google Scholar

Han, Y., Yang, J., Fang, J., Zhou, Y., Candi, E., Wang, J., et al. (2022). The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduct. Target. Ther. 7, 92. doi:10.1038/s41392-022-00932-0

PubMed Abstract | CrossRef Full Text | Google Scholar

Hao, Y., Song, H., Zhou, Z., Chen, X., Li, H., Zhang, Y., et al. (2021). Promotion or inhibition of extracellular vesicle release: emerging therapeutic opportunities. J. Control. Release Off. J. Control. Release Soc. 340, 136–148. doi:10.1016/j.jconrel.2021.10.019

PubMed Abstract | CrossRef Full Text | Google Scholar

Hessvik, N. P., and Llorente, A. (2017). Current knowledge on exosome biogenesis and release. Cell. Mol. Life Sci. CMLS 75 (2), 193–208. doi:10.1007/s00018-017-2595-9

PubMed Abstract | CrossRef Full Text | Google Scholar

Huang, N. F., Stern, B., Oropeza, B. P., Zaitseva, T. S., Paukshto, M. V., and Zoldan, J. (2024). Bioengineering cell therapy for treatment of peripheral artery disease. Arterioscler. Thromb. Vasc. Biol. 44 (3), e66–e81. doi:10.1161/ATVBAHA.123.318126

PubMed Abstract | CrossRef Full Text | Google Scholar

Jang, S. C., Kim, O. Y., Yoon, C. M., Choi, D.-S., Roh, T.-Y., Park, J., et al. (2013). Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano 7 (9), 7698–7710. doi:10.1021/nn402232g

PubMed Abstract | CrossRef Full Text | Google Scholar

Kim, S., Lam, P. Y., Jayaraman, A., and Han, A. (2024). Uniform sized cancer spheroids production using hydrogel-based droplet microfluidics: a review. Biomed. Microdevices 26 (2), 26. doi:10.1007/s10544-024-00712-3

PubMed Abstract | CrossRef Full Text | Google Scholar

Kumar, M. A., Baba, S. K., Sadida, H. Q., Marzooqi, S. A., Jerobin, J., Altemani, F. H., et al. (2024). Extracellular vesicles as tools and targets in therapy for diseases. Signal Transduct. Target. Ther. 9 (1), 1–41. doi:10.1038/s41392-024-01735-1

PubMed Abstract | CrossRef Full Text | Google Scholar

Lee, S.-Y., Koo, I.-S., Hwang, H. J., and Lee, D. W. (2023). In vitro three-dimensional (3D) cell culture tools for spheroid and organoid models. SLAS Discov. 28 (4), 119–137. doi:10.1016/j.slasd.2023.03.006

PubMed Abstract | CrossRef Full Text | Google Scholar

Li, H., Wang, X., Guo, X., Wan, Q., Teng, Y., and Liu, J. (2022). Development of rapamycin-encapsulated exosome-mimetic Nanoparticles-in-PLGA microspheres for treatment of hemangiomas. Biomed. Pharmacother. 148, 112737. doi:10.1016/j.biopha.2022.112737

PubMed Abstract | CrossRef Full Text | Google Scholar

Li, L., Wang, F., Zhu, D., Hu, S., Cheng, K., and Li, Z. (2024). Engineering exosomes and exosome-like nanovesicles for improving tissue targeting and retention. Fundam. Res. 5, 851–867. doi:10.1016/j.fmre.2024.03.025

PubMed Abstract | CrossRef Full Text | Google Scholar

Li, W., Zhang, H., Chen, L., Huang, C., Jiang, Z., Zhou, H., et al. (2025). Cell membrane-derived nanovesicles as extracellular vesicle-mimetics in wound healing. Mater. Today Bio 31, 101595. doi:10.1016/j.mtbio.2025.101595

PubMed Abstract | CrossRef Full Text | Google Scholar

Lorenc, P., Sikorska, A., Molenda, S., Guzniczak, N., Dams-Kozlowska, H., and Florczak, A. (2024). Physiological and tumor-associated angiogenesis: key factors and therapy targeting VEGF/VEGFR pathway. Biomed. Pharmacother. 180, 117585. doi:10.1016/j.biopha.2024.117585

PubMed Abstract | CrossRef Full Text | Google Scholar

Lou, S., Hu, W., Wei, P., He, D., Fu, P., Ding, K., et al. (2025). Artificial nanovesicles derived from cells: a promising alternative to extracellular vesicles. ACS Appl. Mater. Interfaces 17 (1), 22–41. doi:10.1021/acsami.4c12567

PubMed Abstract | CrossRef Full Text | Google Scholar

Lu, R., Zheng, K., Zhou, Y., Wang, W., Zhang, Y., Chen, Y., et al. (2024). 3D spheroid culture synchronizes heterogeneous MSCs into an immunomodulatory phenotype with enhanced anti-inflammatory effects. iScience 27 (9), 110811. doi:10.1016/j.isci.2024.110811

PubMed Abstract | CrossRef Full Text | Google Scholar

Michaelis, U. R. (2014). Mechanisms of endothelial cell migration. Cell. Mol. Life Sci. CMLS 71 (21), 4131–4148. doi:10.1007/s00018-014-1678-0

PubMed Abstract | CrossRef Full Text | Google Scholar

Rajendran, R. L., Gangadaran, P., Oh, J. M., Hong, C. M., and Ahn, B.-C. (2024). Engineering three-dimensional spheroid culture for enrichment of proangiogenic miRNAs in umbilical cord mesenchymal stem cells and promotion of angiogenesis. ACS Omega 9 (39), 40358–40367. doi:10.1021/acsomega.4c02037

PubMed Abstract | CrossRef Full Text | Google Scholar

Rajendran, R. L., Gangadaran, P., Ghosh, S., Nagarajan, A. K., Batabyal, R., and Ahn, B.-C. (2025a). Unlocking the secrets of single extracellular vesicles by cutting-edge technologies. Pathol. Res. Pract. 269, 155878. doi:10.1016/j.prp.2025.155878

PubMed Abstract | CrossRef Full Text | Google Scholar

Rajendran, R. L., Nagarajan, A. K., Oh, J. M., Gangadaran, P., Ramani, P., and Ahn, B.-C. (2025b). “Chapter 2 - overview of the characterization of extracellular vesicles. In extracellular vesicles for therapeutic and diagnostic applications,” in Nanotechnology in biomedicine. Editors K. Anand, C. Vadivalagan, P. Gangadaran, S. Muthu, and B. Peacock (Elsevier), 25–56. doi:10.1016/B978-0-443-23891-8.00001-9

CrossRef Full Text | Google Scholar

Ravi Mythili, V. M., Rajendran, R. L., Arun, R., Thasma Loganathbabu, V. K., Reyaz, D., Nagarajan, A. K., et al. (2025). Emerging strategies for revascularization: use of cell-derived extracellular vesicles and artificial nanovesicles in critical limb ischemia. Bioeng. Basel Switz. 12 (1), 92. doi:10.3390/bioengineering12010092

PubMed Abstract | CrossRef Full Text | Google Scholar

Rovere, M., Reverberi, D., Arnaldi, P., Palamà, M. E. F., and Gentili, C. (2023). Spheroid size influences cellular senescence and angiogenic potential of mesenchymal stromal cell-derived soluble factors and extracellular vesicles. Front. Bioeng. Biotechnol. 11, 1297644. doi:10.3389/fbioe.2023.1297644

PubMed Abstract | CrossRef Full Text | Google Scholar

Samadi, P., Sheykhhasan, M., Mokhtari, K., Yang, P., Maghool, F., and Kalhor, N. (2025). “Chapter 13 - extracellular vesicles: unlocking therapeutic potential in regenerative medicine,” in Extracellular vesicles for therapeutic and diagnostic applications. Editors K. Anand, C. Vadivalagan, P. Gangadaran, S. Muthu, and B. Peacock (Elsevier), 397–435. doi:10.1016/B978-0-443-23891-8.00003-2

CrossRef Full Text | Google Scholar

Samura, M., Hosoyama, T., Takeuchi, Y., Ueno, K., Morikage, N., and Hamano, K. (2017). Therapeutic strategies for cell-based neovascularization in critical limb ischemia. J. Transl. Med. 15 (1), 49. doi:10.1186/s12967-017-1153-4

PubMed Abstract | CrossRef Full Text | Google Scholar

Sun, D., Mou, S., Chen, L., Yang, J., Wang, R., Zhong, A., et al. (2022). High yield engineered nanovesicles from ADSC with enriched miR-21-5p promote angiogenesis in adipose tissue regeneration. Biomater. Res. 26 (1), 83. doi:10.1186/s40824-022-00325-y

PubMed Abstract | CrossRef Full Text | Google Scholar

Sun, L., Ji, Y., Chi, B., Xiao, T., Li, C., Yan, X., et al. (2023). A 3D culture system improves the yield of MSCs-Derived extracellular vesicles and enhances their therapeutic efficacy for heart repair. Biomed. Pharmacother. 161, 114557. doi:10.1016/j.biopha.2023.114557

PubMed Abstract | CrossRef Full Text | Google Scholar

Xue, Z., Liao, Y., and Li, Y. (2024). Effects of microenvironment and biological behavior on the paracrine function of stem cells. Genes Dis. 11 (1), 135–147. doi:10.1016/j.gendis.2023.03.013

PubMed Abstract | CrossRef Full Text | Google Scholar

Yen, B. L., Hsieh, C.-C., Hsu, P.-J., Chang, C.-C., Wang, L.-T., and Yen, M.-L. (2023). Three-dimensional spheroid culture of human mesenchymal stem cells: offering therapeutic advantages and in vitro glimpses of the in vivo state. Stem Cells Transl. Med. 12 (5), 235–244. doi:10.1093/stcltm/szad011

PubMed Abstract | CrossRef Full Text | Google Scholar

Yuksel, A., Velioglu, Y., Cayir, M. C., Kumtepe, G., and Gurbuz, O. (2018). Current status of arterial revascularization for the treatment of critical limb ischemia in infrainguinal atherosclerotic disease. Int. J. Angiol. Off. Publ. Int. Coll. Angiol. Inc. 27 (3), 132–137. doi:10.1055/s-0037-1620242

PubMed Abstract | CrossRef Full Text | Google Scholar

Zemaitis, M. R., Boll, J. M., and Dreyer, M. A. (2025). “Peripheral arterial disease,” in StatPearls (Treasure Island (FL): StatPearls Publishing).

Google Scholar

Keywords: angiogenesis, artificial nanovesicles, ischemia, mesenchymal stem cells, three-dimensional

Citation: Gangadaran P, Rajendran RL, Oh JM, Son J, Hong CM and Ahn B-C (2026) Bioinspired artificial nanovesicles engineered from 3D spheroid-cultured UC-MSCs enhance angiogenic activity in vitro: functional proof-of-concept for ischemic applications. Front. Cell Dev. Biol. 14:1695559. doi: 10.3389/fcell.2026.1695559

Received: 30 August 2025; Accepted: 23 January 2026;
Published: 06 February 2026.

Edited by:

Sabine François, Institut de Recherche Biomédicale des Armées (IRBA), France

Reviewed by:

Divya Sridharan, The Ohio State University, United States
Ingrid Larissa Melo De Souza, Oswaldo Cruz Foundation, Brazil

Copyright © 2026 Gangadaran, Rajendran, Oh, Son, Hong and Ahn. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ramya Lakshmi Rajendran, cmFteWFnQGtudS5hYy5rcg==; Byeong-Cheol Ahn, YWJjMjAwMEBrbnUuYWMua3I=

These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.